RCS - Allergy Therapeutics - PDMR Dealing

Allergy TherapeuticsAnnouncement

03/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230303:nRSC7437Ra&default-theme=true

RNS Number : 7437R  Allergy Therapeutics PLC  03 March 2023

Allergy Therapeutics plc

 ("Allergy Therapeutics" or the "Company")

 PDMR Dealing

Issue of 33,333,332 Warrants

3 March 2023 - Allergy Therapeutics (AIM: AGY), the fully integrated specialty
pharmaceutical company specialising in allergy immunotherapy, today announces
that, further to the Company's announcement on 29 September 2022 regarding the
subscription and debt financing, on 28 February 2023 it issued 33,333,332
warrants to subscribe for new Ordinary Shares ("Warrants").

As previously announced, in conjunction with the issue of Loan Notes, the
Company agreed to issue 33,333,332 Warrants to Southern Fox and ZQ Capital, to
subscribe for new Ordinary Shares at a Warrant Exercise price of 30 pence per
Warrant. The Warrants are exercisable for a period of five years from the
Purchase Date of the Loan Notes.

Following the issue of Warrants Southern Fox and ZQ Capital will hold the
following Warrants over Ordinary Shares in the Company:

·      Southern Fox: 16,666,666 Warrants; and

·      ZQ Capital: 16,666,666 Warrants.

 

Capitalised terms used and not defined in this announcement have the meanings
given to them in the announcement from 29 September 2022.

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0)1903 845 820

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

 

Panmure Gordon (Nominated Adviser and Broker)

+44 (0)20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 (0)20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

  Notification and public disclosure of transactions by Director/persons
discharging managerial responsibilities ("PDMR") and persons closely
associated with them ("PCA")

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Southern Fox Investments Limited

 2   Reason for the notification
 a)  Position/status                                              Persons closely associated Mr. Anthony Parker, Non-Executive Director of
                                                                  Allergy Therapeutics Plc.
 b)  Initial notification/Amendment                               Initial notification.
 3   Details of the issuer, UK emission allowance market participant, auction
     platform or auctioneer
 a)  Name                                                         Allergy Therapeutics Plc
 b)  LEI                                                          213800PQ7AHK7KGVOE23
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Warrant Instrument

 b)  Nature of the transaction                                    Issue of warrants representing subscription rights for ordinary shares of
                                                                  £0.001 each.

 c)  Price(s) and volume(s)                                       Exercise Price(s)                      Volume(s)
     £0.30 per warrant                                                                                   16,666,666

 d)  Aggregated information

     ·      - Aggregated volume                                   n/a

     ·      - Price
 e)  Date of the transaction                                      28 February 2023
 f)  Place of the transaction                                     Outside a trading venue.

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         ZQ Capital Management Limited
 2   Reason for the notification
 a)  Position/status                                              Persons closely associated Mr. Zheqing Shen, Non-Executive Director of Allergy
                                                                  Therapeutics Plc.
 b)  Initial notification/Amendment                               Initial notification.
 3   Details of the issuer, UK emission allowance market participant, auction
     platform or auctioneer
 a)  Name                                                         Allergy Therapeutics Plc
 b)  LEI                                                          213800PQ7AHK7KGVOE23
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Warrant Instrument

 b)  Nature of the transaction                                    Issue of warrants representing subscription rights for ordinary shares of
                                                                  £0.001 each.

 c)  Price(s) and volume(s)                                       Exercise Price(s)                         Volume(s)
     £0.30 (30 pence) per warrant                                                                           16,666,666

 d)  Aggregated information

     ·      - Aggregated volume                                   n/a

     ·      - Price
 e)  Date of the transaction                                      28 February 2023
 f)  Place of the transaction                                     Outside a trading venue.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRANKBBBDBKBQNK